Cargando…

CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond

CD1d-restricted invariant natural killer T (iNKT) cells are considered an attractive target for cancer immunotherapy. Upon their activation by glycolipid antigen and/or cytokines, iNKT cells can induce direct lysis of tumor cells but can also induce an antitumor immune response via their rapid produ...

Descripción completa

Detalles Bibliográficos
Autores principales: King, Lisa A., Lameris, Roeland, de Gruijl, Tanja D., van der Vliet, Hans J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6036112/
https://www.ncbi.nlm.nih.gov/pubmed/30013569
http://dx.doi.org/10.3389/fimmu.2018.01519
_version_ 1783338106259243008
author King, Lisa A.
Lameris, Roeland
de Gruijl, Tanja D.
van der Vliet, Hans J.
author_facet King, Lisa A.
Lameris, Roeland
de Gruijl, Tanja D.
van der Vliet, Hans J.
author_sort King, Lisa A.
collection PubMed
description CD1d-restricted invariant natural killer T (iNKT) cells are considered an attractive target for cancer immunotherapy. Upon their activation by glycolipid antigen and/or cytokines, iNKT cells can induce direct lysis of tumor cells but can also induce an antitumor immune response via their rapid production of proinflammatory cytokines that trigger the cytotoxic machinery of other components of the innate and adaptive immune system. Here, we provide an overview of various therapeutic approaches that have been evaluated or that are currently being developed and/or explored. These include administration of α-GalCer or alternative (glyco) lipid antigens, glycolipid-loaded antigen-presenting cells and liposomes, strategies that enhance CD1d expression levels or are based on ligation of CD1d, adoptive transfer of iNKT cells or chimeric antigen receptor iNKT cells, and tumor targeting of iNKT cells.
format Online
Article
Text
id pubmed-6036112
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-60361122018-07-16 CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond King, Lisa A. Lameris, Roeland de Gruijl, Tanja D. van der Vliet, Hans J. Front Immunol Immunology CD1d-restricted invariant natural killer T (iNKT) cells are considered an attractive target for cancer immunotherapy. Upon their activation by glycolipid antigen and/or cytokines, iNKT cells can induce direct lysis of tumor cells but can also induce an antitumor immune response via their rapid production of proinflammatory cytokines that trigger the cytotoxic machinery of other components of the innate and adaptive immune system. Here, we provide an overview of various therapeutic approaches that have been evaluated or that are currently being developed and/or explored. These include administration of α-GalCer or alternative (glyco) lipid antigens, glycolipid-loaded antigen-presenting cells and liposomes, strategies that enhance CD1d expression levels or are based on ligation of CD1d, adoptive transfer of iNKT cells or chimeric antigen receptor iNKT cells, and tumor targeting of iNKT cells. Frontiers Media S.A. 2018-07-02 /pmc/articles/PMC6036112/ /pubmed/30013569 http://dx.doi.org/10.3389/fimmu.2018.01519 Text en Copyright © 2018 King, Lameris, de Gruijl and van der Vliet. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
King, Lisa A.
Lameris, Roeland
de Gruijl, Tanja D.
van der Vliet, Hans J.
CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
title CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
title_full CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
title_fullStr CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
title_full_unstemmed CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
title_short CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
title_sort cd1d-invariant natural killer t cell-based cancer immunotherapy: α-galactosylceramide and beyond
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6036112/
https://www.ncbi.nlm.nih.gov/pubmed/30013569
http://dx.doi.org/10.3389/fimmu.2018.01519
work_keys_str_mv AT kinglisaa cd1dinvariantnaturalkillertcellbasedcancerimmunotherapyagalactosylceramideandbeyond
AT lamerisroeland cd1dinvariantnaturalkillertcellbasedcancerimmunotherapyagalactosylceramideandbeyond
AT degruijltanjad cd1dinvariantnaturalkillertcellbasedcancerimmunotherapyagalactosylceramideandbeyond
AT vandervliethansj cd1dinvariantnaturalkillertcellbasedcancerimmunotherapyagalactosylceramideandbeyond